<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01600599</url>
  </required_header>
  <id_info>
    <org_study_id>180880</org_study_id>
    <nct_id>NCT01600599</nct_id>
  </id_info>
  <brief_title>Reducing Post Operative Bleeding Following Cabg</brief_title>
  <acronym>LATA</acronym>
  <official_title>Efficacy in Controlling Bleeding Post-coronary Bypass Surgery Using Combination of Local Application of Tranexamic Acid and Intravenous Tranexamic Compared to Intravenous Tranexamic Acid Alone. A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Malaya</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Malaya</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy of IV Tranexamic Acid and topical
      Tranexamic Acid to control post op bleeding following Coronary Artery Bypass Graft Surgery
      using Cardiopulmonary Bypass.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coagulopathy is a common problem after open heart surgery using cardiopulmonary bypass (CPB).
      Some bleeding is significant enough to require early re-exploration to control hemorrhage in
      2-4% of patients.(1,2) In adults, excessive post-operative bleeding occurs in association
      with repeat operations, emergency procedures, female gender, small body mass index, older
      age, peripheral vascular disease, renal insufficiency ( creatinine &gt; 1.8g/dL) , poor
      nutrition ( albumin &lt; 4g/dL) and in patients who have experienced prolonged CPB durations.
      (3,4)

      Factors that contribute to coagulopathy after coronary artery bypass grafting (CABG) using
      CPB include thrombocytopenia, acquired platlet dysfunction, loss of clotting factors, free
      heparin and increased fibrinolysis. (5-7). Lemmer and Colleagues (8) found that
      extracorporeal circulation results in significant fibrinolysis, as reflected by increased
      concentrations of plasmin and fibrin degradation products (FDP), both of which have
      deleterious effects on platlet function. Fibrinolysis was found to be responsible for 25-45%
      of significant post-bypass bleeding. (9)

      Many antifibrinolytic agents have been used to reduce post-bypass bleeding. These include Îµ-
      Aminocaproic Acid (10), Aprotinin (11) and Tranexamic Acid (TA) (12).

      TA has been found to bind to lysine binding sites of plasmin and plasminogen. Saturation of
      these sites displaces plasminogen from the fibrin surface thus inhibiting fibrinolysis.(13).
      TA has been used both systemically and topically.

      Due to the natural barrier properties of the pericardium, which prevents the free diffusion
      of substances, experimental studies have shown that the local application of different
      medications in to the pericardial cavity can lead to desirable therapeutic effects without
      significant systemic absorption. (14-16)

      There has been a systemic review and meta-analysis study done looking at 8 trials (622
      patients) using topical antifibrinolytic agents (aprotinin and tranexamic acid). No adverse
      effects were reported following usage of topical antifibrinolytics.(17)

      Topical TA has also been successfully used in controlling bleeding in bladder,
      gynaecological, oral, &amp; oropharyngeal surgeries. (18-20)

      There has been no authors thus far who have compared application of intravenous TA to
      combination of application of intravenous TA and topical TA.

      This study is based on a hypothesis that the combination of intravenous (IV) TA and topical
      TA administration will significantly reduce the amount of post-op bleeding significantly
      following CABG using CPB.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>chest drain output</measure>
    <time_frame>4 days</time_frame>
    <description>chest drain output (in mls) following post CABG in the 1st hour and total drain output when the drain is removed.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Post CABG Bleeding</condition>
  <arm_group>
    <arm_group_label>IV &amp; topical TA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients in this group will receive both intravenous &amp; topical tranexamic acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV tranexamic acid &amp; Topical Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>intravenous 1g and topical 1g</description>
    <arm_group_label>IV &amp; topical TA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saline</intervention_name>
    <description>100mls of topical saline</description>
    <arm_group_label>IV tranexamic acid &amp; Topical Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  primary isolated CABG

        Exclusion Criteria:

          -  patients who will have combined procedure

          -  redo-surgery

          -  bleeding diathesis (Haemophilia or platelet count ,100 x 109 L1)

          -  renal impairment (Creatinine &gt; 130umol/L)

          -  known allergy to TA

          -  recent (&lt; 7 days before surgery) intake of anti-platelets (eg Aspirin, Clopidogrel,
             Ticlid) or heparin administration within 48 hours of operation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>theevashini krishnasamy, MBChB, MRCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Malaya</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pusat Perubatan University Malaya</name>
      <address>
        <city>Petaling Jaya</city>
        <state>Selangor</state>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <reference>
    <citation>Munoz JJ, Birkmeyer NJ, Dacey LJ, Birkmeyer JD, Charlesworth DC, Johnson ER, Lahey SJ, Norotsky M, Quinn RD, Westbrook BM, O'Connor GT. Trends in rates of reexploration for hemorrhage after coronary artery bypass surgery. Northern New England Cardiovascular Disease Study Group. Ann Thorac Surg. 1999 Oct;68(4):1321-5.</citation>
    <PMID>10543500</PMID>
  </reference>
  <reference>
    <citation>Moulton MJ, Creswell LL, Mackey ME, Cox JL, Rosenbloom M. Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations. J Thorac Cardiovasc Surg. 1996 May;111(5):1037-46.</citation>
    <PMID>8622301</PMID>
  </reference>
  <reference>
    <citation>Magovern JA, Sakert T, Benckart DH, Burkholder JA, Liebler GA, Magovern GJ Sr, Magovern GJ Jr. A model for predicting transfusion after coronary artery bypass grafting. Ann Thorac Surg. 1996 Jan;61(1):27-32.</citation>
    <PMID>8561579</PMID>
  </reference>
  <reference>
    <citation>Despotis GJ, Filos KS, Zoys TN, Hogue CW Jr, Spitznagel E, Lappas DG. Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: a multivariate analysis in cardiac surgical patients. Anesth Analg. 1996 Jan;82(1):13-21.</citation>
    <PMID>8712388</PMID>
  </reference>
  <reference>
    <citation>Kucuk O, Kwaan HC, Frederickson J, Wade L, Green D. Increased fibrinolytic activity in patients undergoing cardiopulmonary bypass operation. Am J Hematol. 1986 Nov;23(3):223-9.</citation>
    <PMID>3766524</PMID>
  </reference>
  <reference>
    <citation>Harker LA, Malpass TW, Branson HE, Hessel EA 2nd, Slichter SJ. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha-granule release. Blood. 1980 Nov;56(5):824-34.</citation>
    <PMID>6448643</PMID>
  </reference>
  <reference>
    <citation>Despotis GJ, Santoro SA, Spitznagel E, Kater KM, Cox JL, Barnes P, Lappas DG. Prospective evaluation and clinical utility of on-site monitoring of coagulation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg. 1994 Jan;107(1):271-9.</citation>
    <PMID>8283896</PMID>
  </reference>
  <reference>
    <citation>Lemmer JH Jr, Stanford W, Bonney SL, Breen JF, Chomka EV, Eldredge WJ, Holt WW, Karp RB, Laub GW, Lipton MJ, et al. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. A multicenter, randomized, double-blind, placebo-controlled study. J Thorac Cardiovasc Surg. 1994 Feb;107(2):543-51; discussion 551-3.</citation>
    <PMID>7508070</PMID>
  </reference>
  <reference>
    <citation>Kevy SV, Glickman RM, Bernhard WF, Diamond LK, Gross RE. The pathogenesis and control of the hemorrhagic defect in open heart surgery. Surg Gynecol Obstet. 1966 Aug;123(2):313-8.</citation>
    <PMID>5913482</PMID>
  </reference>
  <reference>
    <citation>Daily PO, Lamphere JA, Dembitsky WP, Adamson RM, Dans NF. Effect of prophylactic epsilon-aminocaproic acid on blood loss and transfusion requirements in patients undergoing first-time coronary artery bypass grafting. A randomized, prospective, double-blind study. J Thorac Cardiovasc Surg. 1994 Jul;108(1):99-106; discussion 106-8.</citation>
    <PMID>8028387</PMID>
  </reference>
  <reference>
    <citation>Cosgrove DM 3rd, Heric B, Lytle BW, Taylor PC, Novoa R, Golding LA, Stewart RW, McCarthy PM, Loop FD. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. Ann Thorac Surg. 1992 Dec;54(6):1031-6; discussion 1036-8.</citation>
    <PMID>1280411</PMID>
  </reference>
  <reference>
    <citation>Longstaff C. Studies on the mechanisms of action of aprotinin and tranexamic acid as plasmin inhibitors and antifibrinolytic agents. Blood Coagul Fibrinolysis. 1994 Aug;5(4):537-42.</citation>
    <PMID>7531000</PMID>
  </reference>
  <reference>
    <citation>Baek SH, Hrabie JA, Keefer LK, Hou D, Fineberg N, Rhoades R, March KL. Augmentation of intrapericardial nitric oxide level by a prolonged-release nitric oxide donor reduces luminal narrowing after porcine coronary angioplasty. Circulation. 2002 Jun 11;105(23):2779-84.</citation>
    <PMID>12057994</PMID>
  </reference>
  <reference>
    <citation>Kolettis TM, Kazakos N, Katsouras CS, Niokou D, Pappa L, Koulouras V, Stefanou P, Seferiadis C, Malamou-Mitsi V, Michalis LK, Marselos M, Sideris DA. Intrapericardial drug delivery: pharmacologic properties and long-term safety in swine. Int J Cardiol. 2005 Mar 30;99(3):415-21.</citation>
    <PMID>15771922</PMID>
  </reference>
  <reference>
    <citation>Waxman S, Pulerwitz TC, Rowe KA, Quist WC, Verrier RL. Preclinical safety testing of percutaneous transatrial access to the normal pericardial space for local cardiac drug delivery and diagnostic sampling. Catheter Cardiovasc Interv. 2000 Apr;49(4):472-7.</citation>
    <PMID>10751782</PMID>
  </reference>
  <reference>
    <citation>Abrishami A, Chung F, Wong J. Topical application of antifibrinolytic drugs for on-pump cardiac surgery: a systematic review and meta-analysis. Can J Anaesth. 2009 Mar;56(3):202-12. doi: 10.1007/s12630-008-9038-x. Epub 2009 Feb 12. Review.</citation>
    <PMID>19247741</PMID>
  </reference>
  <reference>
    <citation>Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs. 1985 Mar;29(3):236-61. Review.</citation>
    <PMID>2580684</PMID>
  </reference>
  <reference>
    <citation>Valsecchi A. [Further notes on the topical use of tranexamic acid in the treatment of gynecological hemorrhage]. Minerva Ginecol. 1980 Sep;32(9):825-30. Italian.</citation>
    <PMID>7219835</PMID>
  </reference>
  <reference>
    <citation>Sindet-Pedersen S, RamstrÃ¶m G, Bernvil S, BlombÃ¤ck M. Hemostatic effect of tranexamic acid mouthwash in anticoagulant-treated patients undergoing oral surgery. N Engl J Med. 1989 Mar 30;320(13):840-3.</citation>
    <PMID>2648144</PMID>
  </reference>
  <reference>
    <citation>Abul-Azm A, Abdullah KM. Effect of topical tranexamic acid in open heart surgery. Eur J Anaesthesiol. 2006 May;23(5):380-4. Epub 2006 Jan 27.</citation>
    <PMID>16438759</PMID>
  </reference>
  <reference>
    <citation>De Bonis M, Cavaliere F, Alessandrini F, Lapenna E, Santarelli F, Moscato U, Schiavello R, Possati GF. Topical use of tranexamic acid in coronary artery bypass operations: a double-blind, prospective, randomized, placebo-controlled study. J Thorac Cardiovasc Surg. 2000 Mar;119(3):575-80.</citation>
    <PMID>10694619</PMID>
  </reference>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2012</study_first_submitted>
  <study_first_submitted_qc>May 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2012</study_first_posted>
  <last_update_submitted>May 17, 2012</last_update_submitted>
  <last_update_submitted_qc>May 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Malaya</investigator_affiliation>
    <investigator_full_name>Dr Theevashini Krishnasamy, MBChB, MRCS</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

